These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1069558)

  • 21. Discussion paper: tumor-specific transfer factor therapy in osteogenic sarcoma: a two-year study.
    Byers VS; Levin AS; LeCam L; Johnston JO; Hackett AJ
    Ann N Y Acad Sci; 1976; 277(00):621-7. PubMed ID: 1069564
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The host immune response in human osteosarcoma.
    McMaster JH; Ferguson RJ; Weinert CR
    Clin Orthop Relat Res; 1975 Sep; (111):76-82. PubMed ID: 1057466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomaterials-Boosted Immunotherapy for Osteosarcoma.
    Sun C; Li S; Ding J
    Adv Healthc Mater; 2024 Sep; 13(23):e2400864. PubMed ID: 38771618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of resistance to influenza virus infection in animal models.
    Potter CW; McLaren C; Jennings R
    Dev Biol Stand; 1975; 28():307-18. PubMed ID: 1126574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of virus-induced rat osteosarcoma.
    Urovitz EP; Czitrom AA; Langer F; Gross AE; Pritzker PH
    J Bone Joint Surg Am; 1976 Apr; 58(3):308-11. PubMed ID: 1063128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody response to one and two doses of influenza virus subunit vaccine.
    Feery BJ; Cheyne IM; Hampson AW; Atkinson MI
    Med J Aust; 1976 Feb; 1(7):186, 188-9. PubMed ID: 1272148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination.
    Sabarth N; Savidis-Dacho H; Schwendinger MG; Brühl P; Portsmouth D; Crowe BA; Kistner O; Barrett PN; Kreil TR; Howard MK
    Vaccine; 2012 Aug; 30(37):5533-40. PubMed ID: 22749797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progress and opportunities for immune therapeutics in osteosarcoma.
    Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
    Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycan Structures in Osteosarcoma as Targets for Lectin-Based Chimeric Antigen Receptor Immunotherapy.
    Prasse N; Wessolowski C; Müller I; Cornils K; Franke AK
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serologic analysis of human tumor antigens. II. Reactivity of sera from eleven osetogenic sarcoma patients against autologous and allogeneic tumor cells.
    Rosenberg SA; Tondreau SC; Shoffner PC; Hyatt C; Brown JM; Thorpe W; Sindelar W
    Surgery; 1979 Aug; 86(2):258-65. PubMed ID: 288177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review of T-Cell Related Therapy for Osteosarcoma.
    Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for osteosarcoma: Where do we go from here?
    Wedekind MF; Wagner LM; Cripe TP
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
    Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
    Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant chemotherapy associated with surgery in the treatment of osteosarcoma. Preliminary results.
    Bacci G; Pagani PA; Donati U
    Ital J Orthop Traumatol; 1976 Dec; 2(3):363-74. PubMed ID: 1072874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunotherapy of canine osteosarcoma: a historical and systematic review.
    Wycislo KL; Fan TM
    J Vet Intern Med; 2015; 29(3):759-69. PubMed ID: 25929293
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic spinal cord injury attenuates influenza virus-specific antiviral immunity.
    Bracchi-Ricard V; Zha J; Smith A; Lopez-Rodriguez DM; Bethea JR; Andreansky S
    J Neuroinflammation; 2016 May; 13(1):125. PubMed ID: 27245318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.